Health Merger Plan To Face Market

Healthscope and Symbion are expected to reveal details of their alternative merger plans this week Health, after rival Primary Health Care blocked an original $2.9 billion deal Health.Healthscope’s new bid, designed to negate the influence of Symbion’s biggest shareholder, Primary, is believed to involve an asset sale of Symbion’s pathology Health, medical centres and diagnostic imaging businesses to Healthscope.

Health Merger Plan To Face Market It is believed the new deal would be as much as Health Merger. lower than Healthscope’s original offer, which valued Symbion shares at a minimum of $4.36 each. The price put to shareholders, calculated on the basis of Healthscope’s share price in the lead-up to the offer Health, was $4.49 a share. Based on that price, the new offer would value the company at $4.39 a share or $2.84 billion Health.

Healthscope and Symbion have been working on the proposal for almost a month, with analysts concerned about the tax implications of an asset sale Health.But after both parties spent the weekend finalising plans Health, sources expected a new proposal to be announced to the market within days with a shareholder vote set to be held either late this year or early next year Health.